Table of contents
May 2007 Volume 3 No 5
Editorial
Viewpoint
Why hasn't neuroprotection worked in Parkinson's disease?
240Despite encouraging preclinical results, clinical trials of neuroprotective agents for Parkinson's disease have failed to show consistent clinical benefit. In this Viewpoint article, Karl Kieburtz and Bernard Ravina analyze the reasons behind this lack of success and draw conclusions on how to move forward.
Research Highlights
Hippocampal dysfunction associated with depression in temporal lobe epilepsy
242Antimyelin antibodies are not prognostic for progression to multiple sclerosis
242'Benign' multiple sclerosis: difficult to characterize and predict clinical course
242The insula is the critical neural substrate in cigarette addiction
243Memantine and gabapentin are useful in the treatment of congenital nystagmus
243doi:10.1038/ncpneuro0457 | Full Text | PDF (102K)
Neural stem cell grafts differentiate in adult rat spinal cord
244doi:10.1038/ncpneuro0458 | Full Text | PDF (102K)
Prion disease: recovery of cognitive deficits following early intervention
244doi:10.1038/ncpneuro0459 | Full Text | PDF (119K)
Targeted reinnervation enhances control of prosthetic limb
244doi:10.1038/ncpneuro0460 | Full Text | PDF (102K)
Transient orexin receptor blockade induces sleep without cataplexy
245doi:10.1038/ncpneuro0461 | Full Text | PDF (119K)
The PPN is a target for deep brain stimulation in Parkinson's disease
245More-efficient brain circuitry associated with risk of schizophrenia?
246Early benefits of neutralizing antibodies against IFN-
in multiple sclerosis
246Incidence of anticoagulant-associated intracerebral hemorrhage rising in the US
247Practice Points
Antipsychotics in patients with Alzheimer's disease—what is their clinical value?
248Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia
250Antithrombotic treatment and stroke severity in patients with atrial fibrillation
252Reviews
Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution
256Cerebral vasospasm is the classic cause of delayed neurological deterioration after subarachnoid hemorrhage (SAH). Surprisingly, however, patient outcome after SAH was not improved in recent trials of the endothelin antagonist clazosentan, which prevents vasospasm. In light of this result, Macdonald et al. highlight the need for reconsideration of the pathophysiology of SAH.
doi:10.1038/ncpneuro0490 | Full Text | PDF (316K)
Therapy Insight: stroke risk and its management in patients with sickle cell disease
264Children with sickle cell disease present with a variety of neurological syndromes, including ischemic and hemorrhagic stroke. In this Review, Fenella Kirkham describes the clinical and pathological features of stroke in individuals with sickle cell disease, and considers strategies for prevention and management of stroke in this patient population.
doi:10.1038/ncpneuro0495 | Full Text | PDF (741K)
Therapy Insight: inborn errors of metabolism in adult neurology—a clinical approach focused on treatable diseases
279Inborn errors of metabolism account for around a third of all genetic diseases. They can affect many organs, but in most cases they involve the nervous system. This Review focuses on treatable inborn errors of metabolism that can be diagnosed in a neurology department, and proposes guidelines to help neurologists to avoid overlooking treatable metabolic diseases.
doi:10.1038/ncpneuro0494 | Full Text | PDF (288K)
Case Study
A patient with encephalitis associated with NMDA receptor antibodies
291doi:10.1038/ncpneuro0493 | Full Text | PDF (601K)
Article Responses
Revised diagnostic criteria for neuromyelitis optica—incorporation of NMO-IgG status
E1doi:10.1038/ncpneuro0501 | Full Text
